search
Back to results

Lifestyle and Glucose Lowering Medication in T2DM

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
U-TURN
Standard care
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring lifestyle, exercise, physical activity, diet, glycemic control, hba1c, glucose lowering drugs

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Less than three anti-diabetic medications.
  • Diabetes 2 duration of max 10 years
  • BMI >25 but <40 kg/m2,
  • Accept of medical regulation by the UTURN endocrinologists only
  • Accept of purchasing a fitness club membership through U-TURN collaborator

Exclusion Criteria:

  • Hba1c> 9% (75 mmol/mol)
  • Insulin usage
  • Presence of one or more of the following micro- and macrovascular complications of T2DM; a.Diabetic retinopathy (except mild nonproliferative retinopathy or early proliferative retinopathy) b. Macro-albuminuria or nephropathy c. Diabetic neuropathy (except mild affected vibratory testing (<50 Volt)) d. Arterial insufficiency e. Ischemic heart disease
  • Steroid treatment (inhalation) until three months before the medical examination
  • TSH raised/below the normal range
  • Liver disease (ALAT/ASAT thrice normal range)
  • Inability or contraindication to increased levels of physical activity (Pedersen BK and Saltin B)
  • Evidence of anaemia
  • Lung disease (except mild asthma and mild chronic obstructive pulmonary disease)
  • Heart disease
  • Kidney disease (creatinine above 130 µM or macro albuminuria)
  • Pregnancy

Sites / Locations

  • Center for Physical Activity Research, Copenhagen University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

U-TURN intervention

Standard care

Arm Description

The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses. Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.

The reference group will receive diabetes education and support by trained nurses. Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.

Outcomes

Primary Outcome Measures

Change in Hba1c
blood sampling of Hba1c

Secondary Outcome Measures

Change in glucose lowering medication
Change in doses of Metformin, GLP-1 analog, insulin. The change will be evaluate according to changes on the pre-specified regulation algorithm.

Full Information

First Posted
April 6, 2015
Last Updated
December 12, 2018
Sponsor
Rigshospitalet, Denmark
Collaborators
TRYG Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02417012
Brief Title
Lifestyle and Glucose Lowering Medication in T2DM
Official Title
Does Intensive Life Style Intervention Reduce the Need for Glucose Lowering Medications in Patients With Type 2 Diabetes? The U-TURN Project
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
April 2015 (Actual)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
September 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
Collaborators
TRYG Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the effect of a lifestyle intervention maintenance of glycemic control while reducing glucose lowering drugs in patients with type 2 diabetes mellitus. The intervention group receives an intensive lifestyle intervention including exercise and diet lifestyle modifications. The reference group receives diabetes educational advice. Both groups will have their pharmacological treatment regulated across the study. The primary hypothesis is that lifestyle change is sufficient to maintain glycemic control while decreasing the anti-diabetic medication in a sample patients with type 2 diabetes mellitus.
Detailed Description
Adherence to lifestyle modifications including increased exercise and healthy diet improves glycemic control in patients with type 2 diabetes mellitus. However, few have investigated the combined effects of these lifestyle changes on maintenance of glycemic control while decreasing the usage of anti-diabetic medications. The primary hypothesis is that lifestyle change is equivalent in maintaining glycemic control (Hba1c) compared to the standard pharmacological treatment, The U-TURN trial also tests the effects on one key secondary outcome (glucose lowering medication) and examines the effects on sleep quality, fatigue sleepiness, sleep pattern, cardio vascular disease risk factors, psychological outcomes, blood pressure and cholesterol lowering medication. The participants (N=120) is randomized into a experimental group (N=80) and a standard care group (N=40). Additionally, the effects of the study will be evaluated 24 month post randomization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
lifestyle, exercise, physical activity, diet, glycemic control, hba1c, glucose lowering drugs

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
97 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
U-TURN intervention
Arm Type
Experimental
Arm Description
The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses. Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.
Arm Title
Standard care
Arm Type
Active Comparator
Arm Description
The reference group will receive diabetes education and support by trained nurses. Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines.
Intervention Type
Behavioral
Intervention Name(s)
U-TURN
Intervention Description
Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
Intervention Type
Behavioral
Intervention Name(s)
Standard care
Intervention Description
Standard individual diabetes support
Primary Outcome Measure Information:
Title
Change in Hba1c
Description
blood sampling of Hba1c
Time Frame
0, 3, 6, 9, 12 months
Secondary Outcome Measure Information:
Title
Change in glucose lowering medication
Description
Change in doses of Metformin, GLP-1 analog, insulin. The change will be evaluate according to changes on the pre-specified regulation algorithm.
Time Frame
0, 3, 6, 9, 12 months
Other Pre-specified Outcome Measures:
Title
incidence of hypo-glycemic episodes
Description
Self-report to study nurse
Time Frame
0, 3, 6, 9, 12, 24 months
Title
Changes Ldl cholesterol
Description
Blod sampling
Time Frame
0, 3, 6, 9, 12, 24 months
Title
Changes Hdl cholesterol
Description
Blood sampling
Time Frame
0, 3, 6, 9, 12, 24 months
Title
Changes total cholesterol
Description
Blood sampling
Time Frame
0, 3, 6, 9, 12, 24 months
Title
Changes in triglycerides
Description
Blood sampling
Time Frame
0, 3, 6, 9, 12, 24 months
Title
Changes in bdnf-a
Description
Blood sampling
Time Frame
0, 12 months
Title
Change in physical fitness
Description
Progressive treadmill protocol
Time Frame
0, 12, 24 months
Title
Change in body composition (DXA scan)
Description
DXA scan
Time Frame
0, 3, 6, 9, 12, 24 months
Title
Change in sleep quality
Description
Self-report using the PSQI questionnaire
Time Frame
0, 12, months
Title
Change in sleepiness
Description
Self-report using the Epsworth questionnaire
Time Frame
0, 12, months
Title
Change in sleep pattern
Description
Cardio-respiratory monitoring
Time Frame
0, 12, months
Title
Change in the degree of depression
Description
Self-report using the BDI-II questionnaire
Time Frame
0, 12, 24 months
Title
Change in Glucose tolerance (2-h oral glucose tolerance test)
Description
2-h oral glucose tolerance test
Time Frame
0, 12, 24 months
Title
Change in Well-being
Description
Self-report using the questionnaire SF-36 and MFI20
Time Frame
0, 12, 24 months
Title
Change in motivation for exercise
Description
Self-report using the questionnaire BREQ-2
Time Frame
0, 12, 24 months
Title
Change in cognitive function
Description
Self-report using the CANTAB test battery
Time Frame
0, 12 months
Title
Change in arterial function
Description
Arterial function will be determined using flow mediated dilation in a sub set of N=20 patients in each intervention arm (Total N=20)
Time Frame
0, 12 months
Title
Partial T2D remission
Description
No active glucose lowering medication and HbA1c<48 mmol/mol and Fasting blood glucose<6,9 mmol/l
Time Frame
24 months
Title
Full T2D remission
Description
No active glucose lowering medication and HbA1c<39 mmol/mol and Fasting blood glucose<5.6 mmol/l
Time Frame
24 months
Title
Change in low grade inflammation
Description
The change in pro- and anti inflammatory markers will be evaluated
Time Frame
0, 12, 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Less than three anti-diabetic medications. Diabetes 2 duration of max 10 years BMI >25 but <40 kg/m2, Accept of medical regulation by the UTURN endocrinologists only Accept of purchasing a fitness club membership through U-TURN collaborator Exclusion Criteria: Hba1c> 9% (75 mmol/mol) Insulin usage Presence of one or more of the following micro- and macrovascular complications of T2DM; a.Diabetic retinopathy (except mild nonproliferative retinopathy or early proliferative retinopathy) b. Macro-albuminuria or nephropathy c. Diabetic neuropathy (except mild affected vibratory testing (<50 Volt)) d. Arterial insufficiency e. Ischemic heart disease Steroid treatment (inhalation) until three months before the medical examination TSH raised/below the normal range Liver disease (ALAT/ASAT thrice normal range) Inability or contraindication to increased levels of physical activity (Pedersen BK and Saltin B) Evidence of anaemia Lung disease (except mild asthma and mild chronic obstructive pulmonary disease) Heart disease Kidney disease (creatinine above 130 µM or macro albuminuria) Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mathias Ried-Larsen, PhD
Organizational Affiliation
Rigshospitalet, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Physical Activity Research, Copenhagen University Hospital
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
16451303
Citation
Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports. 2006 Feb;16 Suppl 1:3-63. doi: 10.1111/j.1600-0838.2006.00520.x.
Results Reference
background
PubMed Identifier
35764194
Citation
Legaard GE, Feineis CS, Johansen MY, Hansen KB, Vaag AA, Larsen EL, Poulsen HE, Almdal TP, Karstoft K, Pedersen BK, Ried-Larsen M. Effects of an exercise-based lifestyle intervention on systemic markers of oxidative stress and advanced glycation endproducts in persons with type 2 diabetes: Secondary analysis of a randomised clinical trial. Free Radic Biol Med. 2022 Aug 1;188:328-336. doi: 10.1016/j.freeradbiomed.2022.06.013. Epub 2022 Jun 25.
Results Reference
derived
PubMed Identifier
34431828
Citation
Abildgaard J, Johansen MY, Skov-Jeppesen K, Andersen LB, Karstoft K, Hansen KB, Hartmann B, Holst JJ, Pedersen BK, Ried-Larsen M. Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Med Sci Sports Exerc. 2022 Jan 1;54(1):38-46. doi: 10.1249/MSS.0000000000002776.
Results Reference
derived
PubMed Identifier
33441418
Citation
MacDonald CS, Nielsen SM, Bjorner J, Johansen MY, Christensen R, Vaag A, Lieberman DE, Pedersen BK, Langberg H, Ried-Larsen M, Midtgaard J. One-year intensive lifestyle intervention and improvements in health-related quality of life and mental health in persons with type 2 diabetes: a secondary analysis of the U-TURN randomized controlled trial. BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001840. doi: 10.1136/bmjdrc-2020-001840.
Results Reference
derived
PubMed Identifier
32816096
Citation
Johansen MY, Karstoft K, MacDonald CS, Hansen KB, Ellingsgaard H, Hartmann B, Wewer Albrechtsen NJ, Vaag AA, Holst JJ, Pedersen BK, Ried-Larsen M. Effects of an intensive lifestyle intervention on the underlying mechanisms of improved glycaemic control in individuals with type 2 diabetes: a secondary analysis of a randomised clinical trial. Diabetologia. 2020 Nov;63(11):2410-2422. doi: 10.1007/s00125-020-05249-7. Epub 2020 Aug 20.
Results Reference
derived
PubMed Identifier
32007295
Citation
MacDonald CS, Johansen MY, Nielsen SM, Christensen R, Hansen KB, Langberg H, Vaag AA, Karstoft K, Lieberman DE, Pedersen BK, Ried-Larsen M. Dose-Response Effects of Exercise on Glucose-Lowering Medications for Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial. Mayo Clin Proc. 2020 Mar;95(3):488-503. doi: 10.1016/j.mayocp.2019.09.005. Epub 2020 Jan 30.
Results Reference
derived
PubMed Identifier
28810024
Citation
Johansen MY, MacDonald CS, Hansen KB, Karstoft K, Christensen R, Pedersen M, Hansen LS, Zacho M, Wedell-Neergaard AS, Nielsen ST, Iepsen UW, Langberg H, Vaag AA, Pedersen BK, Ried-Larsen M. Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 Aug 15;318(7):637-646. doi: 10.1001/jama.2017.10169.
Results Reference
derived
PubMed Identifier
26656025
Citation
Ried-Larsen M, Christensen R, Hansen KB, Johansen MY, Pedersen M, Zacho M, Hansen LS, Kofoed K, Thomsen K, Jensen MS, Nielsen RO, MacDonald C, Langberg H, Vaag AA, Pedersen BK, Karstoft K. Head-to-head comparison of intensive lifestyle intervention (U-TURN) versus conventional multifactorial care in patients with type 2 diabetes: protocol and rationale for an assessor-blinded, parallel group and randomised trial. BMJ Open. 2015 Dec 9;5(12):e009764. doi: 10.1136/bmjopen-2015-009764.
Results Reference
derived

Learn more about this trial

Lifestyle and Glucose Lowering Medication in T2DM

We'll reach out to this number within 24 hrs